PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B VIRUS: Guidelines on antiviral prophylaxis in pregnancy July 2020

(1)

i

PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B

VIRUS: Guidelines on antiviral prophylaxis in pregnancy

July 2020

Web Annex F. Summary of declared interests of Guideline Development Group

members

(2)

ii

Prevention of mother-to-child transmission of hepatitis B virus (HBV): guidelines on antiviral prophylaxis in pregnancy. Web Annex F. Summary of declared interests of Guideline Development Group members ISBN 978-92-4-000867-0 (electronic version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation:

“This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Web Annex F. Summary of declared interests of Guideline Development Group members. In:

Prevention of mother-to-child transmission of hepatitis B virus (HBV): guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication.

However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication forms part of the WHO guideline entitledPrevention of mother-to-child transmission of hepatitis B virus (HBV): guidelines on antiviral prophylaxis in pregnancy. It is being made publicly available for transparency purposes and information, in accordance with the WHO handbook for guideline development, 2nd edition (2014).

(3)

3

Declared interests Guidelines Developments Group members

Participants Declared interests Declared amount Level of participation

Jourdain

Gonzague

Personal: Sanofi shares

Institutional: Research grant on viral hepatitis elimination symposium by Gilead.

Provision of study drugs for clinical trial by Gilead

US$14,320 US$32,605

Restricted

Su wang Personal: Advisory board, Gilead and Janssen Institutional: Research grant HBV and HCV screening program in Emergency Department, Gilead

US$8,000, US$400 US$230,000

Restricted

Indri Sukmaputri (Chair)

Personal: None Institutional: None

Full

Fernanda Fernandes Fonseca

Full

Manal Hamdy El- Sayed

Personal: None

Institutional: PI in clinical trial to treat HCV infection in children undergoing chemotherpy

Full

Fernando de la Hoz

Full

Jinlin Hou Personal: None Institutional: None

Full

Deborah Odoh Personal: None Institutional: None

Full

Rakesh Aggarwal Personal: None Institutional: None

Full

Olivier Segeral Personal: None Institutional: None

Full

(4)

4 Nii Akwei Addo Personal: None

Institutional: None

Full

Alice Guingane Personal: None Institutional: None

Full

Cihan Yurdaydin Personal: None Institutional: None

Full

Elizabeth Mason Personal: None Institutional: None

Full

Adenyi

Oluwafunmilayo

Full

Huma Qureshi Personal: None Institutional: None

Full

Roger Chou (methodologist)

Full

Benjamin Cowie Personal: None Institutional: None

Full

Hiromi Obara Personal: None Institutional: None

Full

Sarah Schillie Personal: None Institutional: None

Full

Njie Ramatoulie Personal: None Institutional: None

Full

Ailing Wang Personal: None Institutional: None

Full

Chipepo Kankasa Personal: None Institutional: None

Full

(5)

5

Declared interests Peer Review Group members

Name Declared interests Declared amount Conflict and management plan

Karen Kyuregyan Personal: None Institutional: None

None

Mark Sonderup Personal: None

Institutional: Funding for Hepatitis project ECHO from Gilead

Comments interpreted in the

context of conflict of interest.

No substantive changes were made based on this review Michelle Gilles Personal: None

Institutional: None

None

Samual So Personal: None Institutional: None

None

Zheng Hui Personal: None Institutional: None

None

Kathy Jackson Personal: None Institutional: None

None

Gilles Wandeler Personal: None

Institutional: Research grant from Gilead and travel grants from Gilead and Abb Vie

CHF 980,000 CHF 6,000

Comments interpreted in the context of conflict of interest.

No substantive changes were made based on this review Christian Ramers Personal: Advisory board AbbVie

and Gilead

Institutional: research support Abb Vie and Gilead

USD 18,000 USD 750,000

Comments interpreted in the context of conflict of interest.

No substantive changes were made based on this review Nikoloz Chkhartishvili Personal: None

Institutional: None

None

(6)

6

Name and title Affiliation, City, Country WHO region M/F Area of expertise

Chipepo Kankasa Department of Paediatrics

and Child Health, University teaching Hospital, Lusaka, Zambia

AFRO F Paediatric Infectious diseases including Center of

Excellence for HIV, hepatitis, malaria

Ramou Njie IARC, based at the research station in Gambia

AFRO F Longitudinal follow up of mother/infant pairs in the Gambia project

Funmi Adeniyi Department of Paediatrics, University of Lagos teaching Hospital

AFRO F Paediatric Infectious diseases

Nii Akwei Addo Public Health consultant, past programme manager

AFRO M HIV PMTCT expert

Alice Guingané University Hospital of Yalgado, Ouagadougou, Burkina Faso

AFRO F Implementation of large HBV PMTCT project using

antivirals Deborah Odoh Ministry of Health, Abuja

Nigeria

AFRO F National programme

manager HIV PMTCT Dr. Benjamin Cowie Royal Melbourne Hospital,

Melbourne Australia

WPRO M Implementation of

programmes; WHO collaborating center Hiromi Obara National Center for Global

Health, Japan

WPRO F Technical expert in Mother and Child Health

Jinlin Hou Former APASL president and professor at Southern Medical University, Guangzhou, China

WPRO M Implementation expert in China and PI of the SHIELD project for HBV in 100 hospitals

Olivier Ségéral Inserm-ANRS, Cambodia WPRO M Researcher, TA PROHM study (EMTCT HBV)

(7)

7

Wang Ailing NCMCH China WPRO F Triple elimination expert

Manal Hamdy El- Sayed

Ain Shams University Egypt EMRO F Pediatrics and expert in hepatitis B and C Huma Qureshi Pakistan Medical Research

Council

EMRO M Programme implementation

in Pakistan and Afghanistan, including PWID

Elizabeth Mason Independent consultant EURO F Previous director of MNCH at WHO; technical expert and STAC member

Cihan Yurdaydin University of Ankara Medical School

EURO M Hepatologist and expert in HBV and HBV/HDV treatment

Gonzague Jourdain PHTP Thailand SEARO M Principal investigator of two HBV PMTCT trials

Rakesh Aggarwal Institute of Medical Education and Research, India

SEARO M Research

Indri Oktaria Sukmaputri

Ministry of Health, Jakarta, Indonesia

SEARO F Head of Hepatitis prevention and control

Sarah Schillie CDC AMRO F Technical expert; coordinator

of US CDC guidelines on this topic

Su Wang World hepatitis Alliance board member

AMRO F Representative civil society and persons living with viral hepatitis

Fernando de la Hoz University of Colombia AMRO M Research

Fernanda Fonseca Ministry of Health, Brazil AMRO F Programme and implementation expert

(8)

8